EGFR and lung carcinoma: Forward genetic screens represent powerful tools to identify mechanisms of drug resistance – here we used genome-scale loss (CRISPRn) and gain (CRISPRa) of function CRISPR screens to identify genes and pathways complicit in resistance (or persistence) to EGFR inhibitors in EGFR mutant lung cancer.